Yu Waye Chu
Chief Tech/Sci/R&D Officer chez CYTOMX THERAPEUTICS, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Yu Waye Chu occupe le poste de premier vice-président chargé du développement clinique chez Fate Therapeutics, Inc. Il a obtenu un diplôme de premier cycle à l'université de Princeton et un doctorat à l'école de médecine et de dentisterie de l'université de Rochester.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
FATE THERAPEUTICS, INC.
0,14% | 18/04/2023 | 140 676 ( 0,14% ) | 1 M $ | 31/03/2024 |
18/01/2024 | 26 250 ( 0,04% ) | 57 225 $ | 31/03/2024 |
Postes actifs de Yu Waye Chu
Sociétés | Poste | Début |
---|---|---|
CYTOMX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17/07/2023 |
Anciens postes connus de Yu Waye Chu
Sociétés | Poste | Fin |
---|---|---|
FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 14/07/2023 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/04/2019 |
Formation de Yu Waye Chu
Princeton University | Undergraduate Degree |
University of Rochester School of Medicine & Dentistry | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
FATE THERAPEUTICS, INC. | Health Technology |
CYTOMX THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |